Class Ib: P-gp Efflux + Additional Mechanism | Class II: Weak or No P-gp Efflux + Additional Impairment | Class IV: P-gp Efflux - Compensatory Mechanism(s) | ||||||
---|---|---|---|---|---|---|---|---|
Drug | Additional Evidence | Drug | Additional Evidence | Drug | Additional Evidence | |||
Cetirizine (C) | Very low permeability (Mahar Doan et al., 2002) | Cimetidine (Ci) | Non-P-gp efflux transporter(s) (www.tp-search.jp) | Methadone (M) | Active uptake (Chi and Dixit, 1977) | |||
Digoxin (Dg) | Additional efflux transporter(s) (www.tp-search.jp) | Dexamethasone (Dex) | Steroid transporter (Pariante et al., 2001) | Ritonavir (Rit) | Active uptake (Anthonypillai et al., 2004) | |||
Doxorubicin (Dox) | Additional efflux transporter(s) (www.tp-search.jp) | Fexofenadine (Fex) | Reduced CNS activity (Hindmarch et al., 2002) | Saquinavir (Sq) | Active uptake (Su et al., 2004) | |||
Ivermectin (Iv) | Additional efflux transporter(s) (Lespine et al., 2006) | Ranitidine (Ra) | Non-P-gp efflux transporter(s) (Bourdet et al., 2005) | |||||
Sumatriptan (Sum) | Very low permeability (Mahar Doan et al., 2002) | |||||||
|
| Zolmitriptan (Z) | Very low permeability (Mahar Doan et al., 2002) |
|
|